- Transaction expected to combine
Accelus andCHP Merger Corp. , a leading healthcare-focused SPAC. - The pro-forma enterprise value of the business combination would be approximately
$482 million . Chris Walsh , Accelus CEO and Co-Founder, will become CEO of the combined company, Accelus.Mr. Walsh has 25 years of experience at leading spinal health companies, including Stryker and NuVasive.Joseph Swedish , Chairman ofCHP Merger Corp. , and seasoned industry executiveAlex Lukianov will join the Board of Directors of the combined company.Mr. Swedish has decades of healthcare industry experience having served in positions at Anthem,Trinity Health ,Centura and HCA Healthcare.Mr. Lukianov has over 35 years of leadership and entrepreneurial experience across several leading medical technology companies, including NuVasive,BackCare Group , Smith & Nephew and Medtronic.
Company Overview
Based in
Management Comments
Transaction Overview
On
The proposed transaction has been unanimously approved by the boards of directors of each of
Additional information about the proposed transaction, including a copy of the business combination agreement and an investor presentation, will be provided in a Current Report on Form 8-K to be filed today by
Advisors
Piper Sandler is serving as exclusive financial advisor to Accelus.
Credit Suisse is serving as financial and capital markets advisor, and
Management Presentation and Webcast Details
A webcast of the corporate presentation and associated materials is available on Deal Roadshow:
Deal Roadshow Investor Login Details
URL: https://dealroadshow.com
Direct Link: ACCELUS2021
Entry Code: https://dealroadshow.com/e/ACCELUS2021
About Accelus
Accelus is committed to accelerating minimally invasive spine surgery through its enabling technology with broad accessibility to previously underserved markets. Established through the combination of Integrity Implants and Fusion Robotics, Accelus is focused on providing its proprietary Adaptive GeometryTM technology with pragmatic and economical navigation and robotic solutions with broad clinical use in spine surgery. Learn more at www.accelusinc.com.
About
Important Information about the Business Combination and Where to Find It
In connection with the proposed business combination (the “Business Combination”),
Participants in the Solicitation
CHP and its directors and executive officers may be deemed participants in the solicitation of proxies from CHP’s shareholders with respect to the Business Combination. You can find information about CHP’s directors and executive officers and their ownership of CHP’s securities in CHP’s Annual Report on Form 10-K for the fiscal year ended
Accelus and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of CHP in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the Business Combination will be contained in the Registration Statement when available.
Forward-Looking Statements
No representations or warranties are made or implied with respect to the information contained herein. This press release contains forward-looking statements with respect to CHP and Accelus. These forward-looking statements, by their nature, require us to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, including without limitation the successful and timely completion of the proposed business combination. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks and strategies or deliverables stated herein, may involve, but are not limited to, comments with respect to effects of the proposed business combination, CHP business or financial objectives, its strategies or future actions, its projections, targets, expectations for financial condition or outlook for operations. Words such as “may,” “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative or comparable terminology, as well as terms usually used in the future and conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. These assumptions are considered to be reasonable based on currently available information, but the reader is cautioned that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect our business. The forward-looking information set forth herein reflects expectations as of the date hereof and is subject to change thereafter. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Undue reliance should not be placed on forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. This press release is not intended to form the basis of any investment decision and there can be no assurance that any transaction will be undertaken or completed in whole or in part. The delivery of this press release shall not be taken as any form of commitment on the part of Accelus, CHP or their respective shareholders to proceed with any transaction, and no offers will subject Accelus, CHP or their respective shareholders to any contractual obligations before definitive documentation has been executed. We reserve the right at any time without prior notice and without any liability to (i) negotiate with one or more prospective investors in accordance with any timetable and on any terms that we may decide, (ii) provide different information or access to information to different prospective investors, (iii) enter into definitive documentation and (iv) terminate the process, including any negotiations with any prospective investor without giving any reasons therefor. This press release does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of CHP, Accelus, or any of their respective affiliates.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
Contacts
info@concordhp.com
Accelus Investor Contact:
Gilmartin Group
ir@accelusinc.com
Source: Accelus
2021 GlobeNewswire, Inc., source